A randomized phase I study of two different schedules of BAY 43-9006 [sorafenib] in patients with acute myeloid leukemia or myelodysplastic syndrome
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2010
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 01 Feb 2010 Results published in Leukemia and Lymphoma.
- 10 Feb 2006 New trial record.